The novel SGLT2 inhibitor showed significant heart-protective effects in preclinical diabetes models, improving cardiac function,reducing heart muscle damage, and lowering oxidative stress while managing blood sugar. This evidence concerns the gene SLC5A2 and diabetes mellitus.